药物治疗肝纤维化临床研究进展  

Drug Treatment of Liver Fibrosis on Clinical Trials

作　　者：王会清[1] 段毅力[1] 

机构地区：[1]天津市传染病医院特需病房,天津300192

出　　处：《医学综述》2010年第17期2676-2678,共3页Medical Recapitulate

摘　　要：肝纤维化是当前国内外关于慢性肝病的研究热点与难点,对其发生机制已有所认识,但临床治疗方面仍欠缺突破性的方案。在国外学者看来最好的抗纤维化策略是减少或抑制潜在疾病,对于不同原因造成的肝病需要不同的药物治疗。我国目前对干扰素及核苷(酸)的抗病毒及抗纤维化作用研究较多,并且我国具有独特的祖国医学及前人经验,中药单方及复方制剂研究及应用较多,中西药联合治疗有效的报道很多,其作用机制还有待进一步研究。The study of liver fibrosis is the current research focus on chronic liver disease worldwide.Its mechanisms have been recognized,but its clinical treatment still lacks breakthrough.Western researchers deem the best antifibrotic regimen to improve or control the underlying diseases.Different liver diseases requires different drug therapies.Currently,Chinese investigators have studied extensively on anti-viral and anti-fibrotic actions of interferons and nucleosides（nucleic acids）,based on unique traditional Chinese medicines and predecessors＇ experience including more research and application of singular and compound preparations.Traditional combination therapies have been reported but the mechanisms of action need further study.

关 键 词：肝纤维化 药物 临床方案 

分 类 号：R575.2[医药卫生—消化系统]